{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T19:56:45Z","timestamp":1763755005061,"version":"3.45.0"},"reference-count":19,"publisher":"Oncology Nursing Society (ONS)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CJON"],"published-print":{"date-parts":[[2020,4,1]]},"DOI":"10.1188\/20.cjon.129-133","type":"journal-article","created":{"date-parts":[[2020,3,20]],"date-time":"2020-03-20T11:18:12Z","timestamp":1584703092000},"page":"129-133","source":"Crossref","is-referenced-by-count":1,"title":["Peptide Receptor Radionuclide Therapy: An Emerging Treatment for Gastrointestinal Neuroendocrine Tumors"],"prefix":"10.1188","volume":"24","author":[{"given":"Adria","family":"Myers","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Holly","family":"Chitwood","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1302","published-online":{"date-parts":[[2020,4,1]]},"reference":[{"key":"1","unstructured":"Advanced Accelerator Applications. (2018). Lutathera\u00ae (lutetium Lu 177 dotatate) [Package insert]. http:\/\/bit.ly\/39ZXQtd"},{"key":"2","doi-asserted-by":"crossref","unstructured":"Bergsma, H., van Lom, K., Raaijmakers, M.H.G.P., Konijnenberg, M., Kam, B.L.B.L.R., Teunissen, J.J.M., . . . Kwekkeboom, D.J. (2018). Persistent hematologic dysfunction after peptide receptor radionuclide therapy with 177Lu-DOTATATE: Incidence, course, and predicting factors in patients with gastroenteropancreatic neuroendocrine tumors. Journal of Nuclear Medicine, 59(3), 452\u2013458.","DOI":"10.2967\/jnumed.117.189712"},{"key":"3","doi-asserted-by":"crossref","unstructured":"Bosquet, C., Casta\u00f1o, J.P., Csaba, Z., Culler, M., Dournaud, P., Epelbaum, J., Feniuk, W., . . . Wester, H.-J. (2019). Somatostatin receptors (version 2019.4) in the IUPHAR\/BPS guide to pharmacology database. IUPHAR\/BPS Guide to Pharmacology CITE, 2019(4). https:\/\/doi.org\/10.2218\/gtopdb\/F61\/2019.4","DOI":"10.2218\/gtopdb\/F61\/2019.4"},{"key":"4","doi-asserted-by":"crossref","unstructured":"Bruinooge, S.S., Pickard, T.A., Vogel, W., Hanley, A., Schenkel, C., Garrett-Mayer, E., . . . Williams, S.F. (2018). Understanding the role of advanced practice providers in oncology in the United States. Journal of Oncology Practice, 14(9), e518\u2013e532. https:\/\/doi.org\/10.1200\/JOP.18.00181","DOI":"10.1200\/JOP.18.00181"},{"key":"5","unstructured":"Chacko, C.A., Chauhan, A., El Khouli, R., & Anthony, L. (2019). Lutetium 177-DOTATATE therapy in progressive metastatic well-differentiated G1\/G2 neuroendocrine tumors: Review of the University of Kentucky\u2019s post-FDA approval PRRT program. https:\/\/bit.ly\/2xdS20J"},{"key":"6","unstructured":"Christopoulos, C., & Papavassiliou, E. (2005). Gastric neuroendocrine tumors: Biology and management. Annals of Gastroenterology, 18(2), 127\u2013140."},{"key":"7","doi-asserted-by":"crossref","unstructured":"Dasari, A., Shen, C., Halperin, D., Zhao, B., Zhou, S., Xu, Y., . . . Yao, J.C. (2017). Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncology, 3(10), 1335\u20131342.","DOI":"10.1001\/jamaoncol.2017.0589"},{"key":"8","doi-asserted-by":"crossref","unstructured":"Hennrich, U., & Kopka, K. (2019). Lutathera\u00ae: The first FDA- and EMA-approved radiopharmaceutical for peptide receptor radionuclide therapy. Pharmaceuticals, 12(3), 114.","DOI":"10.3390\/ph12030114"},{"key":"9","doi-asserted-by":"crossref","unstructured":"Kaltsas, G.A., Besser, G.M., & Grossman, A.B. (2004). The diagnosis and medical management of advanced neuroendocrine tumors. Endocrine Reviews, 25(3), 458\u2013511.","DOI":"10.1210\/er.2003-0014"},{"key":"10","doi-asserted-by":"crossref","unstructured":"Mittra, E.S. (2018). Neuroendocrine tumor therapy: 177Lu-DOTATATE. American Journal of Roentgenology, 211, 278\u2013285. https:\/\/doi.org\/10.2214\/AJR.18.19953","DOI":"10.2214\/AJR.18.19953"},{"key":"11","doi-asserted-by":"crossref","unstructured":"\u00d6berg, K. (2017). Medical therapy of gastrointestinal neuroendocrine tumors. Visceral Medicine, 33(5), 352\u2013356.","DOI":"10.1159\/000475831"},{"key":"12","doi-asserted-by":"crossref","unstructured":"Oronsky, B., Ma, P.C., Morgensztern, D., & Carter, C.A. (2017). Nothing but NET: A review of neuroendocrine tumors and carcinomas. Neoplasia, 19(12), 991\u20131002.","DOI":"10.1016\/j.neo.2017.09.002"},{"key":"13","doi-asserted-by":"crossref","unstructured":"Raphael, M.J., Chan, D.L., Law, C., & Singh, S. (2017). Principles of diagnosis and management of neuroendocrine tumours. Canadian Medical Association Journal, 189(10), E398\u2013E404. https:\/\/doi.org\/10.1503\/cmaj.160771","DOI":"10.1503\/cmaj.160771"},{"key":"14","doi-asserted-by":"crossref","unstructured":"Rolleman, E.J., Valkema, R., de Jong, M., Kooij, P., & Krenning, E.P. (2003). Safe and effective inhibition of renal uptake of radiolabelled octreotide by a combination of lysine and arginine. European Journal of Nuclear Medicine and Molecular Imaging, 30(1), 9\u201315.","DOI":"10.1007\/s00259-002-0982-3"},{"key":"15","doi-asserted-by":"crossref","unstructured":"Sackstein, P.E., O\u2019Neil, D.S., Neugut, A.I., Chabot, J., & Fojo, T. (2018). Epidemiologic trends in the neuroendocrine tumors: An examination of incidence rates and survival of specific patient subgroups over the past 20 years. Seminars in Oncology, 45(4), 249\u2013258.","DOI":"10.1053\/j.seminoncol.2018.07.001"},{"key":"16","doi-asserted-by":"crossref","unstructured":"Sampathirao, N., & Basu, S. (2017). MIB-1 index-stratified assessment of dual-tracer PET\/CT with 68Ga-DOTATATE and 18F-FDG and multimodality anatomic imaging in metastatic neuroendocrine tumors of unknown primary in a PRRT workup setting. Journal of Nuclear Medicine Technology, 45(1), 34\u201341.","DOI":"10.2967\/jnmt.116.185777"},{"key":"17","doi-asserted-by":"crossref","unstructured":"Sorbye, H., Baudin, E., & Perren, A. (2018). The problem of high-grade gastroenteropancreatic neuroendocrine neoplasms: Well-differentiated neuroendocrine tumors, neuroendocrine carcinomas, and beyond. Endocrinology and Metabolism Clinics of North America, 47(3), 683\u2013698.","DOI":"10.1016\/j.ecl.2018.05.001"},{"key":"18","doi-asserted-by":"crossref","unstructured":"Tzontcheva, A. (2010). Neuroendocrine tumors: Laboratory diagnosis. Journal of Medical Biochemistry, 29(4), 254\u2013264. https:\/\/doi.org\/10.2478\/v10011-010-0028-5","DOI":"10.2478\/v10011-010-0028-5"},{"key":"19","unstructured":"Williams, E.D., & Sandler, M. (1963). The classification of carcinoid tumours. Lancet, 281(7275), 238\u2013239."}],"container-title":["Clinical Journal of Oncology Nursing"],"original-title":[],"link":[{"URL":"http:\/\/cjon.ons.org\/cjon\/24\/2\/peptide-receptor-radionuclide-therapy-emerging-treatment-gastrointestinal-neuroendocrine","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T19:50:23Z","timestamp":1763754623000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ons.org\/publications-research\/cjon\/24\/2\/peptide-receptor-radionuclide-therapy-emerging-treatment"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,1]]},"references-count":19,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,4,1]]}},"URL":"https:\/\/doi.org\/10.1188\/20.cjon.129-133","relation":{},"ISSN":["1092-1095","1538-067X"],"issn-type":[{"type":"print","value":"1092-1095"},{"type":"electronic","value":"1538-067X"}],"subject":[],"published":{"date-parts":[[2020,4,1]]}}}